Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months. The extension provides participants the opportunity to continue on treatment, ...
Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent ...
A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...
On Saturday April 5, Anavex announced data from their open-label extension trial, ATTENTION-AD, for early Alzheimer's Disease presented at the AD/PDTM 2025 Conference. ATTENTION-AD is a follow-on ...
Rationale and study design of the KOV-HIPEC-04: A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS). This is an ASCO ...
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial Patients with stage III to IV or recurrent, radiographically ...
Pfizer Inc ($PFE) announced an update on their ongoing clinical study. PFE’s New Liver Cancer Trial: Early Signal to Watch The study, officially ...
ATHLONE, Ireland--(BUSINESS WIRE)--Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, announced today that the following clinical trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback